Skip to content

AUSTRALASIA

One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form (“FDF”) solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.

Key Countries

Australia
New Zealand

KEY BRANDS

Brand Therapeutic category
Circadin Sleeping aid
Eltroxin/Eutroxsig/Oroxine Thyroid hormone replacement
range
Maltofer Iron supplement
Ural Womens’ health
Xylocaine &
Adrenaline
Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

538

June 2021

531

June 2020

pg4-graph1

STATISTICS

Number of products launched:

2

(2020: 2)

Number of product recalls:

Nil

(2020: 2)

Average staff turnover:

8%

(2020: 9%)

Number of work-related fatalities:

Nil

(2020: Nil)

Sales representatives:

74

(2020: 70)

Revenue 2021
R’million
2020 (CER)
R’million
Change
%
Total Commercial Pharmaceuticals 4 867 4 623 5
Regional Brands 4 113 3 876 6
Sterile Focus Brands 754 747 1
Manufacturing – FDF 554 430 29
Total 5 421 5 053 7

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.

  • The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021.

Source: IQVIA – August 2020
*MAT = Moving annual total

Scroll To Top